Elicera Therapeutics recently announced the publication of a scientific article describing the mechanism-of-action of its universal CAR T-cell enhancement technology platform iTANK. The publication came in Nature Biomedical Engineering, one of the highest ranked scientific journals in the world. CSO and co-founder Professor Magnus Essand joined BioStock Studio via link from Uppsala to tell us more about iTANK and the importance of this publication.